1Austin HA. Therapy of lupus nephritis: controlled trial of prednisone and cytoxic drugs. New Engl J Med, 1986, 314:614-619.
2Vasquez S, Kavanaugh AF, Schneider NR, et al. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol,1992, 19: 1625.
3Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis, 1998, 32: 318-322.
4Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 2000,343: 1156-1162.
6Dooley MA, Cosio FG, Patrick H, et al. Mycophenolate mofetiltherapy in lupus nephritis: clinical observations. J Am Soc Nephrol, 1999, 10: 833-839.
7Layne D. Non-transplant uses of mycophenolate mofetil. Curr Opin Nephrol Hypertens, 1999, 8: 563.
8Flanc RS, Roberts MA, Strippoli GF, et al.Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials.Am J Kidney Dis,2004,43:197-208.
9Breedveld FC, Dayer JM.Leflunomide: mode of action in the treatment of rheumatoid arthritis.Ann Rheum Dis, 2000,59:841-849.
10Li EK, Tam LS, Tomlinson B.Leflunomide in the treatment of rheumatoid arthritis.Clin Ther,2004,26: 447-459.
